Single-Domain ILT4 Antibody for Tumor Checkpoint Resistance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immune checkpoint therapy for tumors is inadequate, necessitating the development of drugs targeting new and alternative checkpoint molecules like ILT4 to enhance anti-tumor immunotherapy.
Innovation Solution
Development of an anti-ILT4 single-domain antibody or antigen-binding fragment with specific CDR sequences and immunoglobulin Fc region, capable of binding ILT4 with high affinity and modulating immune responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional immune checkpoint therapy is used, then some anti-tumor effect is achieved, but the success rate falls short of expectations
Solution Approach 1:
The patent changes the target parameter from conventional immune checkpoint molecules to ILT4, a newly identified checkpoint molecule. By shifting the target parameter, the therapy achieves improved success rates and anti-tumor effectiveness, resolving the contradiction between conventional therapy limitations and therapeutic efficacy requirements.
2Productivity
If new checkpoint molecules like ILT4 are targeted, then anti-tumor immunotherapy is enhanced, but drug development complexity increases
Solution Approach 1:
The patent segments the antibody structure into distinct functional regions: complementarity determining regions (CDRs) for high-affinity ILT4 binding, and immunoglobulin Fc regions for immune system engagement. This segmentation allows optimized performance in each region while managing overall development complexity through modular design.
Solution Approach 2:
The patent uses single-domain antibodies as intermediary molecules that specifically bind to ILT4 on tumor cells and immune cells. This intermediary approach enables precise targeting of the ILT4 pathway, enhancing anti-tumor therapy effectiveness while providing a clear developmental pathway that manages complexity through a well-defined mechanism of action.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antibody effectively targets ILT4, enhancing anti-tumor immune responses and providing therapeutic benefits beyond conventional therapies.
Implementation Method 1
the single-domain antibody or antigen-binding fragment thereof comprises CDR1, CDR2 and CDR3, wherein the CDR1, CDR2 and CDR3 comprise, respectively, an amino acid sequence as shown in SEQ ID NOs: 1-3
Data Source
AI summary
Provided is an anti-ILT4 single-domain antibody and antigen-binding fragment thereof. Also provided are a method of using it for the treatment or prevention of a disease in a subject, and a method of preparing the antibody and antigen-binding fragment thereof.